Focus Partners Advisor Solutions LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Focus Partners Advisor Solutions LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 849 shares of the biopharmaceutical company’s stock, valued at approximately $538,000.

Other hedge funds also recently made changes to their positions in the company. Marietta Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock valued at $6,836,000 after buying an additional 2,501 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after buying an additional 814,713 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Regeneron Pharmaceuticals by 3.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock valued at $16,255,000 after buying an additional 955 shares during the last quarter. KBC Group NV raised its holdings in shares of Regeneron Pharmaceuticals by 9.4% during the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company’s stock valued at $94,779,000 after buying an additional 12,793 shares during the last quarter. Finally, Lmcg Investments LLC raised its holdings in shares of Regeneron Pharmaceuticals by 231.3% during the first quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company’s stock valued at $9,184,000 after buying an additional 10,110 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.6%

Regeneron Pharmaceuticals stock opened at $567.22 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm has a market cap of $60.12 billion, a price-to-earnings ratio of 14.29, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,175.16. The firm’s 50 day moving average price is $561.54 and its two-hundred day moving average price is $585.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $11.56 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on REGN. Argus cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research note on Monday, August 4th. Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Finally, Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.